The global epidermolysis bullosa therapeutics market is expected to post a CAGR of nearly 5% during the period 2019-2023, according to the latest market research report by Technavio.
Treatments with low side effects are yet to be developed for the treatment of this condition, even with the significant research activities undertaken over the past several decades. Hence, many government and private organizations are increasing their investments towards the advancement of research to develop therapeutics that have better safety and efficacy than the available medications for the treatment of epidermolysis bullosa.
As per Technavio, the development of gene therapy will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global epidermolysis bullosa therapeutics market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Global epidermolysis bullosa therapeutics market: Development of gene therapy
Regenerative medicines such as gene therapy are one of the most advanced and heavily researched treatment methods. In gene therapy, the mutated gene is taken from the patient and is modified genetically in the laboratory, which is then administered back into the patient. Therefore, the mutated genes are replaced by the genetically modified gene.
At present, a few gene therapies are approved globally, these therapies have proven to be highly effective for the treatment of various indications. This resulted in several companies conducting clinical trials using gene therapy for the treatment of epidermolysis bullosa. Majority of these studies are still in the clinical trial phase, says a senior analyst at Technavio.
Global epidermolysis bullosa therapeutics market: Segmentation analysis
This market research report segments the global epidermolysis bullosa therapeutics market by product (antibiotics, analgesics, and other therapeutics) and geographical regions (North America, Europe, Asia, and ROW).
The antibiotics segment held the largest market share in 2018, accounting for nearly 43% of the market. This product segment is expected to dominate the global market throughout the forecast period.
North America led the market in 2018 with a market share of over 32%. This region is expected to dominate the market through 2023. However, there will be a decrease in its market share.
Looking for more information on this market? Request a free sample report
Technavios sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200